The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients

BACKGROUND: Tacrolimus is available as twice-daily Prograf® (Tac-BID) and the once-daily formulation, Advagraf® (Tac-OD). Although therapeutically equivalent, some transplant recipients require dose adjustments to achieve similar tacrolimus trough concentrations [Tac C(0)] after conversion between f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaltzman, Alina S. R, Glick, Lauren A., Zaltzman, Jeffrey S., Nash, Michelle, Huang, Michael, Prasad, G. V. Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730664/
https://www.ncbi.nlm.nih.gov/pubmed/26823971
http://dx.doi.org/10.1186/s13737-016-0031-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730664/
https://www.ncbi.nlm.nih.gov/pubmed/26823971
http://dx.doi.org/10.1186/s13737-016-0031-6

Ejemplares similares